WEBULL
News
AUTL
1.560
-0.64%
-0.010
Autolus Therapeutics Appoints Ryan Richardson to Board
TipRanks · 2d ago
Weekly Report: what happened at AUTL last week (1124-1128)?
Weekly Report · 4d ago
Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?
Benzinga · 11/25 17:37
Midday Fly By: Alphabet continues ascent, fueled by AI optimism
TipRanks · 11/25 17:06
Abercrombie & Fitch, Titan Machinery, Zoom Communications, Woodward And Other Big Stocks Moving Higher On Tuesday
Benzinga · 11/25 15:03
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/25 12:05
Autolus Therapeutics announces NICE draft guidance recommending Aucatzyl
TipRanks · 11/25 10:10
Autolus Wins UK Backing for New CAR-T Cancer Therapy AUCATZYL for Adults With Aggressive Leukemia
Benzinga · 11/25 09:07
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
Barchart · 11/25 03:00
Weekly Report: what happened at AUTL last week (1117-1121)?
Weekly Report · 11/24 09:48
Weekly Report: what happened at AUTL last week (1110-1114)?
Weekly Report · 11/17 09:48
A Fresh Look at Autolus Therapeutics (AUTL) Valuation Following Earnings, Obe-cel Expansion, and Anticipated ASH Data
Simply Wall St · 11/15 10:22
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline
Seeking Alpha · 11/14 15:28
Can Autolus Therapeutics' (AUTL) Expanding Obe-cel Reach Bolster Its Position in Cell Therapy?
Simply Wall St · 11/14 07:35
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Autolus Therapeutics (AUTL)
TipRanks · 11/13 16:11
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Barchart · 11/13 15:05
Autolus Therapeutics (AUTL) Gets a Buy from Truist Financial
TipRanks · 11/13 13:06
Wells Fargo Keeps Their Buy Rating on Autolus Therapeutics (AUTL)
TipRanks · 11/13 12:06
Autolus Therapeutics Reports Q3 2025 Financial Results
TipRanks · 11/13 03:56
Autolus Therapeutics’ Earnings Call: Mixed Sentiments
TipRanks · 11/13 00:02
More
Webull provides a variety of real-time AUTL stock news. You can receive the latest news about AUTOLUS THERAPEUTICS PLC through multiple platforms. This information may help you make smarter investment decisions.
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.